导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.46% | 3064/4773 |
| 近一周 | -1.96% | 3188/5465 |
| 近一月 | - | 700/5421 |
| 近一季 | 1.57% | 702/5231 |
| 近半年 | -3.16% | 2409/4920 |
| 近一年 | 1.92% | 2390/4394 |
| 近两年 | 28.53% | 2351/2954 |
| 近三年 | 22.58% | 1393/2253 |
| 成立以来 | 101.49% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.90% 2961/4961 |
-4.77% 3526/5312 |
- - |
- - |
| 2025 | 12.00% 2714/4813 |
-1.00% 2524/3635 |
2.78% 1363/4076 |
5.41% 3591/4524 |
4.43% 531/4813 |
| 2024 | 20.30% 474/3463 |
6.92% 272/2808 |
2.60% 335/3014 |
14.19% 2030/3129 |
-3.96% 2410/3463 |
| 2023 | -2.13% 559/2656 |
3.09% 1266/2280 |
-0.36% 378/2385 |
1.36% 315/2515 |
-6.01% 1592/2655 |
| 2022 | -10.18% 201/2207 |
-6.94% 231/1919 |
2.13% 1345/2016 |
-9.67% 295/2113 |
4.62% 529/2208 |
| 2021 | 2.30% 635/1822 |
1.56% 250/1255 |
-0.27% 1136/1330 |
-0.60% 497/1466 |
1.61% 861/1822 |
| 2020 | 21.73% 686/1250 |
-11.69% 846/1028 |
6.06% 872/1067 |
16.34% 156/1164 |
11.71% 525/1184 |
| 2019 | 26.69% 571/1092 |
21.90% 586/754 |
0.60% 167/804 |
-2.30% 693/850 |
5.74% 682/918 |
| 2018 | -19.34% 160/834 |
- - |
- - |
- - |
-12.10% 400/691 |
| 2017 | 22.96% 141/714 |
- - |
- - |
- - |
- - |
| 2016 | -6.57% 199/605 |
- - |
- - |
- - |
- - |
| 2015 | -3.18% 271/575 |
- - |
- - |
- - |
- - |
| 2014 | 69.15% 14/237 |
- - |
- - |
- - |
- - |
| 2013 | -7.74% 130/186 |
- - |
- - |
- - |
- - |
| 2012 | 14.17% 19/140 |
- - |
- - |
- - |
- - |
| 2011 | -19.79% 35/102 |
- - |
- - |
- - |
- - |
| 2010 | -18.07% 47/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 交银上证180公司治理ETF VS. 长安沪深300非周期A(740101) |